tram-34 and Inflammatory-Bowel-Diseases

tram-34 has been researched along with Inflammatory-Bowel-Diseases* in 3 studies

Other Studies

3 other study(ies) available for tram-34 and Inflammatory-Bowel-Diseases

ArticleYear
Histone Deacetylases Enhance Ca
    International journal of molecular sciences, 2018, Sep-27, Volume: 19, Issue:10

    The up-regulated expression of the Ca

    Topics: Animals; CD4-Positive T-Lymphocytes; Cells, Cultured; Histone Deacetylase Inhibitors; Histone Deacetylases; Inflammatory Bowel Diseases; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Potassium Channel Blockers; Pyrazoles

2018
Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, May-15, Volume: 306, Issue:10

    The intermediate-conductance Ca(2+)-activated K(+) channel KCa3.1/KCNN4 plays an important role in the modulation of Ca(2+) signaling through the control of the membrane potential in T lymphocytes. Here, we study the involvement of KCa3.1 in the enlargement of the mesenteric lymph nodes (MLNs) in a mouse model of inflammatory bowel disease (IBD). The mouse model of IBD was prepared by exposing male C57BL/6J mice to 5% dextran sulfate sodium for 7 days. Inflammation-induced changes in KCa3.1 activity and the expressions of KCa3.1 and its regulators in MLN CD4(+) T lymphocytes were monitored by real-time PCR, Western blot, voltage-sensitive dye imaging, patch-clamp, and flow cytometric analyses. Concomitant with an upregulation of KCa3.1a and nucleoside diphosphate kinase B (NDPK-B), a positive KCa3.1 regulator, an increase in KCa3.1 activity was observed in MLN CD4(+) T lymphocytes in the IBD model. Pharmacological blockade of KCa3.1 elicited the following results: 1) a significant decrease in IBD disease severity, as assessed by diarrhea, visible fecal blood, inflammation, and crypt damage of the colon and MLN enlargement compared with control mice, and 2) the restoration of the expression levels of KCa3.1a, NDPK-B, and Th1 cytokines in IBD model MLN CD4(+) T lymphocytes. These findings suggest that the increase in KCa3.1 activity induced by the upregulation of KCa3.1a and NDPK-B may be involved in the pathogenesis of IBD by mediating the enhancement of the proliferative response in MLN CD4(+) T lymphocyte and, therefore, that the pharmacological blockade of KCa3.1 may decrease the risk of IBD.

    Topics: Animals; CD4-Positive T-Lymphocytes; Dextran Sulfate; Disease Models, Animal; DNA-Binding Proteins; Inflammatory Bowel Diseases; Intermediate-Conductance Calcium-Activated Potassium Channels; Lymph Nodes; Male; Mice; Mice, Inbred C57BL; NM23 Nucleoside Diphosphate Kinases; Nuclear Proteins; Pyrazoles; Ubiquitin-Protein Ligases; Up-Regulation

2014
A high-throughput screening campaign for detection of ca(2+)-activated k(+) channel activators and inhibitors using a fluorometric imaging plate reader-based tl(+)-influx assay.
    Assay and drug development technologies, 2013, Volume: 11, Issue:3

    The intermediate-conductance Ca(2+)-activated K(+) channel (KCa3.1) has been proposed to play many physiological roles, and modulators of KCa3.1 activity are potentially interesting as new drugs. In order to identify new chemical scaffolds, high-throughput screening (HTS) assays are needed. In the current study, we present an HTS assay that has been optimized for the detection of inhibitors as well as activators of KCa3.1 in a combined assay. We used HEK293 cells heterologously expressing KCa3.1 in a fluorescence-based Tl(+) influx assay, where the permeability of potassium channels to Tl(+) is taken advantage of. We found the combined activator-and-inhibitor assay to be robust and insensitive to dimethyl sulfoxide (up to 1%), and conducted an HTS campaign of 217,119 small molecules. In total, 224 confirmed activators and 312 confirmed inhibitors were found, which corresponded to a hit rate of 0.10% and 0.14%, respectively. The confirmed hits were further characterized in a fluorometric imaging plate reader-based concentration-response assay, and selected compounds were subjected to secondary testing in an assay for endogenous KCa3.1 activity using human erythrocytes (red blood cell assay). Although the estimated potencies were slightly higher in the RBC assay, there was an overall good correlation across all clusters. The campaign led to the identification of several chemical series of KCa3.1 activators and inhibitors, comprising already known pharmacophores and new chemical series. One of these were the benzothiazinones that constitute a new class of highly potent KCa3.1 inhibitors, exemplified by 4-{[3-(trifluoromethyl)phenyl]methyl}-2H-1,4-benzothiazin-3(4H)-one (NS6180).

    Topics: Acetamides; Algorithms; Data Interpretation, Statistical; Erythrocytes; Fluorometry; HEK293 Cells; High-Throughput Screening Assays; Humans; Inflammatory Bowel Diseases; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Pyrazoles; Small Molecule Libraries; Thallium; Thiazines; Trityl Compounds

2013